These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26560244)

  • 1. Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression.
    Schaefer-Klein JL; Murphy SJ; Johnson SH; Vasmatzis G; Kovtun IV
    PLoS One; 2015; 10(11):e0142327. PubMed ID: 26560244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
    Karnes RJ; Cheville JC; Ida CM; Sebo TJ; Nair AA; Tang H; Munz JM; Kosari F; Vasmatzis G
    Cancer Res; 2010 Nov; 70(22):8994-9002. PubMed ID: 21062978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
    Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
    Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
    Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
    Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
    Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
    de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
    J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
    Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
    Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the androgen receptor pathway during progression of prostate cancer.
    Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
    Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
    Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
    Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
    Zolochevska O; Figueiredo ML
    Prostate; 2009 Oct; 69(14):1586-97. PubMed ID: 19585490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha.
    Hua W; Sa KD; Zhang X; Jia LT; Zhao J; Yang AG; Zhang R; Fan J; Bian K
    Biochem Biophys Res Commun; 2015 Aug; 463(4):1077-83. PubMed ID: 26079880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival.
    Murata T; Takayama K; Urano T; Fujimura T; Ashikari D; Obinata D; Horie-Inoue K; Takahashi S; Ouchi Y; Homma Y; Inoue S
    Clin Cancer Res; 2012 Oct; 18(20):5617-27. PubMed ID: 22904106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells.
    Margiotti K; Wafa LA; Cheng H; Novelli G; Nelson CC; Rennie PS
    Mol Cancer; 2007 Jun; 6():38. PubMed ID: 17553164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic herpesvirus HHV-8 promotes androgen-independent prostate cancer growth.
    Mygatt JG; Singhal A; Sukumar G; Dalgard CL; Kaleeba JA
    Cancer Res; 2013 Sep; 73(18):5695-708. PubMed ID: 24005834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
    Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
    Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.